Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Chemistry

Biochemistry

Medicine

Cancer Oncology

Internal Medicine

Show all topics

DOI

10.1016/s1470-2045(11)70214-5